Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Paul Freeman OD, FAAO, FOVDR
Paul B. Freeman OD, FAAO, FOVDR Editor-in-Chief
Leonard Press OD, FAAO, FCOVD
Leonard J. Press OD, FAAO, FCOVD Associate Editor
Esther Bowie MD
Esther M. Bowie MD Advisory Board
See All Experts
featured
Published in Eye Care

Journal Scan / Research · October 12, 2022

Outcomes of Low-Dose vs Very Low–Dose Bevacizumab Treatment in Infants With Retinopathy of Prematurity

Ophthalmology

 

 Save  Recommend
 Share

Additional Info

Ophthalmology
Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes
Ophthalmology 2022 Oct 01;129(10)1120-1128, SF Freedman, A Hercinovic, DK Wallace, RT Kraker, Z Li, AR Bhatt, CS Boente, ER Crouch, GB Hubbard, DL Rogers, D VanderVeen, MB Yang, NL Cheung, SA Cotter, JM Holmes,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated